Pasithea Therapeutics Announces Adjournment of Reconvened Meeting of Stockholders to December 29, 2023

by divibasicbldev | Dec 28, 2023 | Press Releases

SOUTH SAN FRANCISCO, Calif. and MIAMI, Dec. 28, 2023 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (“Pasithea” or the “Company”) (NASDAQ: KTTA) today announced that its meeting of stockholders, which had been partially adjourned on...

Pasithea Therapeutics Announces Results from 2023 Annual Meeting

by divibasicbldev | Dec 19, 2023 | Press Releases

— Solicitation Continues for Certain Charter Amendment Proposals -SOUTH SAN FRANCISCO, Calif. and MIAMI, Dec. 19, 2023 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (“Pasithea” or the “Company”) (NASDAQ: KTTA), today announced that...

Pasithea Therapeutics Announces Positive In Vivo Preclinical Efficacy Data for PAS-004 from NRAS Mutation Cancer Xenograft Models

by divibasicbldev | Dec 11, 2023 | Press Releases

— Preclinical data continues to demonstrate PAS-004’s potentially superior properties as compared to FDA approved MEK inhibitors — — Once daily dose of PAS-004 delivers anti-tumor efficacy in in vivo NRAS mutation cancer models — SOUTH...

Pasithea Therapeutics Announces Adjournment of 2023 Annual Meeting of Stockholders

by divibasicbldev | Nov 29, 2023 | Press Releases

SOUTH SAN FRANCISCO, Calif. and MIAMI, Nov. 29, 2023 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (“Pasithea” or the “Company”) (NASDAQ: KTTA), today announced that its annual meeting of stockholders held on November 29, 2023 (the...

Pasithea Therapeutics Announces Outcome of Pre-IND Meeting with FDA for PAS-004 Clinical Development

by divibasicbldev | Nov 29, 2023 | Press Releases

— Company on track to submit PAS-004 IND application in current quarter — — Pasithea plans to begin PAS-004 Phase 1 dose escalation trial in advanced solid tumor patients harboring RAS, RAF and NF1 mutations — SOUTH SAN FRANCISCO, Calif. and...